ASH 2014 | Phase I study shows nivolumab is safe and tolerable for relapsed or refractory Hodgkin lymphoma

Philippe Armand

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Philippe Armand (Dana-Farber Cancer Institute, Boston, MA) discusses the results of a phase I study evaluating the preliminary efficacy and safety of PD-1 inhibitor, nivolumab, in patients with relapsed or refractory classical Hodgkin lymphoma.

Share this video  
Similar topics